# US 2020/0392149 A1 · Substituted pyrrolidine compound and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392149 A1
- Document ID: US20200392149A1
- Status: Published application
- Kind: A1
- Application number: 16/491,794
- Filed: 2018-03-07
- Published: 2020-12-17
- Earliest claimed: 2017-03-08
- Assignees: Takeda Pharmaceutical Company Limited
- Applicants: Takeda Pharmaceutical Company Limited
- Inventors: Satoshi MIKAMI; Masaki DAINI; Yuhei MIYANOHANA; Hideo SUZUKI; Kenichiro SHIMOKAWA; Yuichi KAJITA; Masaki OGINO; Tatsuki KOIKE; Kohei TAKEUCHI
- Web page: https://patentgrep.com/patent/US20200392149A1

## CPC

- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/4035: Isoindoles, e.g. phthalimide
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/438: The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/26: Psychostimulants, e.g. nicotine, cocaine
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/04: Antibacterial agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 207/09: Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D 207/12: Oxygen or sulfur atoms
- C07D 207/14: Nitrogen atoms not forming part of a nitro radical
- C07D 207/16: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/10: linked by a carbon chain containing aromatic rings
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 413/10: linked by a carbon chain containing aromatic rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

## Claims

### Claim 1

A compound represented by the formula (I):
wherein
X1, X2, X3 and X4 are each independently a nitrogen atom, or CRa;
Y is an oxygen atom, NRb, or CRcRd;
R1 is an optionally substituted C1-6 alkyl group, an optionally substituted hydrocarbon ring group, or an optionally substituted heterocyclic group bonded on the carbon atom;
R2 is a hydrogen atom, or an optionally substituted C1-6 alkyl group;
R3 is an optionally substituted C1-6 alkyl group, or an optionally substituted cyclic group;
Ring A is an optionally further substituted pyrrolidine ring;
Ra, Rc and Rd are each independently a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, or an optionally substituted C1-6 alkoxy group; and
Rb is a hydrogen atom, or an optionally substituted C1-6 alkyl group,
or a salt thereof.

### Claim 2 (depends on 1)

The compound or salt according to claim 1, wherein
X1 is a nitrogen atom, or CRa wherein Ra is a hydrogen atom, a halogen atom or a C1-6 alkyl group;
X2 is a nitrogen atom, or CRa wherein Ra is a hydrogen atom, a halogen atom or a C1-6 alkyl group;
X3 is a nitrogen atom, or CRa wherein Ra is a hydrogen atom, a halogen atom or a C1-6 alkyl group;
X4 is a nitrogen atom, or CRa wherein Ra is a hydrogen atom or a halogen atom;
Y is
(1) an oxygen atom,
(2) NRb wherein Rb is
(a) a hydrogen atom, or
(b) a C1-6 alkyl group optionally substituted by 1 to 3 substituents selected from
(i) a C1-6 alkoxy group, and
(ii) a mono- or di-C1-6 alkyl-carbamoyl group, or
(3) CH2;
R1 is
(1) a C1-6 alkyl group,
(2) a C3-10 cycloalkyl group,
(3) a C6-14 aryl group optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom,
(b) a C1-6 alkoxy group,
(c) a C6-14 aryl group optionally substituted by 1 to 3 mono- or di-C1-6 alkyl-carbamoyl groups, and
(d) a pyrrolidyl group, a piperidyl group, a morpholinyl group and a 1-oxa-8-azaspiro[5.5]undecyl group, each optionally substituted by 1 to 3 substituents selected from
(i) an oxo group,
(ii) a C1-6 alkyl-carbonyl group,
(iii) a mono- or di-C1-6 alkylamino group,
(iv) a pyridyl group, and
(v) a pyrrolidylcarbonyl group,
(4) a thienyl group or a pyridyl group, each optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom,
(b) a C1-6 alkoxy group, and
(c) a mono- or di-C1-6 alkyl-carbamoyl group, or
(5) a tetrahydropyranyl group, a piperidyl-3-yl group or an isoindolin-5-yl group, each optionally substituted by 1 to 3 C1-6 alkyl-carbonyl groups;
R2 is a hydrogen atom, or a C1-6 alkyl group optionally substituted by 1 to 3 halogen atoms;
R3 is
(1) a C1-6 alkyl group optionally substituted by 1 to 3 substituents selected from a C6-14 aryl group optionally substituted by 1 to 3 C1-6 alkoxy groups,
(2) a C6-14 aryl group optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom,
(b) a C1-6 alkyl group optionally substituted by 1 to 3 halogen atoms,
(c) a C1-6 alkoxy group optionally substituted by 1 to 3 halogen atoms,
(d) a mono- or di-C1-6 alkylamino group,
(e) a C1-6 alkylsulfanyl group, and
(f) a morpholinyl group,
(3) a pyrazolyl group, a thienyl group or a pyridyl group, each optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom,
(b) a C1-6 alkyl group optionally substituted by 1 to 3 halogen atoms, and
(c) a C6-14 aryl group,
(4) a tetrahydropyranyl group or a dihydrobenzofuryl group, or
(5) a C3-10 cycloalkyl group optionally substituted by 1 to 3 C6-14 aryl groups; and
Ring A is a pyrrolidine ring optionally further substituted by 1 to 3 substituents selected from
(a) a halogen atom,
(b) a hydroxy group,
(c) a cyano group,
(d) a C1-6 alkyl group optionally substituted by 1 to 3 substituents selected from
(i) a halogen atom, and
(ii) a C1-6 alkoxy group,
(e) a C1-6 alkoxy group optionally substituted by 1 to 3 halogen atoms,
(f) a mono- or di-C1-6 alkyl-carbamoyl group,
(g) an amino group,
(h) a mono- or di-C1-6 alkylamino group, and
(i) a C1-6 alkyl-carbonylamino group.

### Claim 3 (depends on 1)

The compound or salt according to claim 1, wherein
X1 is CRa wherein Ra is a hydrogen atom, a halogen atom or a C1-6 alkyl group;
X2 is CH;
X3 is a nitrogen atom, or CRa wherein Ra is a hydrogen atom, a halogen atom or a C1-6 alkyl group;
X4 is a nitrogen atom or CH;
Y is an oxygen atom;
R1 is
(1) a C1-6 alkyl group,
(2) a phenyl group optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom,
(b) a C1-6 alkoxy group, and
(c) a phenyl group optionally substituted by 1 to 3 mono- or di-C1-6 alkyl-carbamoyl groups, or
(3) a thienyl group optionally substituted by 1 to 3 halogen atoms;
R2 is a hydrogen atom;
R3 is
(1) a C1-6 alkyl group optionally substituted by 1 to 3 substituents selected from a phenyl group optionally substituted by 1 to 3 C1-6 alkoxy groups,
(2) a phenyl group optionally substituted by 1 to 3 substituents selected from
(a) a C1-6 alkyl group, and
(b) a C1-6 alkoxy group, or
(3) a pyrazolyl group optionally substituted by 1 to 3 substituents selected from a C1-6 alkyl group optionally substituted by 1 to 3 halogen atoms; and
Ring A is a pyrrolidine ring optionally further substituted by one substituent selected from
(a) a halogen atom,
(b) a C1-6 alkyl group, and
(c) a C1-6 alkoxy group.

### Claim 4 (depends on 1)

The compound or salt according to claim 1, wherein
X1 is CRa wherein Ra is a hydrogen atom or a halogen atom;
X2 is CH;
X3 is CH;
X4 is CH;
Y is an oxygen atom;
R1 is a phenyl group optionally substituted by 1 to 3 substituents selected from
(a) a C1-6 alkoxy group, and
(b) a phenyl group optionally substituted by 1 to 3 mono- or di-C1-6 alkyl-carbamoyl groups;
R2 is a hydrogen atom;
R3 is a phenyl group optionally substituted by 1 to 3 C1-6 alkyl groups; and
Ring A is a pyrrolidine ring optionally further substituted by one C1-6 alkoxy group.

### Claim 5

3′-((3-(((3S)-1-(2,6-Dimethylbenzoyl)pyrrolidin-3-yl)oxy)phenyl)sulfamoyl)-4′-methoxy-N,N-dimethylbiphenyl-3-carboxamide or a salt thereof.

### Claim 6

N-(3-(((3R,4R)-1-(2,5-Dimethylbenzoyl)-4-methoxypyrrolidin-3-yl)oxy)phenyl)-2-methoxybenzenesulfonamide or a salt thereof.

### Claim 7

3′-((3-(((3S)-1-(2,6-Dimethylbenzoyl)pyrrolidin-3-yl)oxy)-2-fluorophenyl)sulfamoyl)-4′-methoxy-N,N-dimethylbiphenyl-3-carboxamide or a salt thereof.

### Claim 8 (depends on 1)

A medicament comprising the compound or salt according to claim 1.

### Claim 9 (depends on 8)

The medicament according to claim 8, which is an orexin type 2 receptor agonist.

### Claim 10 (depends on 8)

The medicament according to claim 8, which is an agent for the prophylaxis or treatment of narcolepsy.

### Claim 11 (depends on 1)

The compound or salt according to claim 1 for use in the prophylaxis or treatment of narcolepsy.

### Claim 12 (depends on 1)

A method of activating an orexin type 2 receptor in a mammal, which comprises administering an effective amount of the compound or salt according to claim 1 to the mammal.

### Claim 13 (depends on 1)

A method for the prophylaxis or treatment of narcolepsy in a mammal, which comprises administering an effective amount of the compound or salt according to claim 1 to the mammal.

### Claim 14 (depends on 1)

Use of the compound or salt according to claim 1 for the manufacture of an agent for the prophylaxis or treatment of narcolepsy.
